암 치료제 시장 : 투여 경로, 치료 유형, 유형, 최종사용자별 - 세계 예측(2025-2030년)

The Cancer Drugs Market was valued at USD 144.50 billion in 2023, expected to reach USD 157.76 billion in 2024, and is projected to grow at a CAGR of 9.57%, to USD 274.05 billion by 2030.

The cancer drugs market encompasses a diverse range of therapeutic solutions aimed at treating various forms of cancer. This market includes chemotherapy, immunotherapy, targeted therapy, hormone therapy, and other innovative treatments. The necessity of cancer drugs is underscored by the rising prevalence of cancer globally, advancing medical technology, and increasing awareness about early detection and treatment options. These drugs find application across multiple end-users such as hospitals, clinics, and specialized cancer treatment centers. Key influencing factors for market growth include heightened investment in R&D by pharmaceutical companies, significant advancements in precision medicine, and the increasing approval rates of new cancer drugs. The surge in geriatric population and lifestyle changes further expedite the demand for effective cancer treatments. Potential opportunities lie in the rising adoption of personalized medicine and the growing acceptance of biosimilars, which provide cost-effective treatment alternatives. Companies can leverage these opportunities by intensifying their focus on developing biosimilars and precision medicine tailored to individual patient profiles. However, the market also faces limitations such as high costs of drug development, rigorous regulatory requirements, and the complex nature of cancer pathophysiology, which can hamper innovation and market entry. Additionally, side effects associated with cancer treatments pose challenges to widespread acceptance. Innovation and research could pivot towards enhancing drug delivery systems, exploring combination therapies, and leveraging AI for early diagnosis and personalized treatment plans, thereby offering businesses growth avenues while improving patient outcomes. The cancer drugs market is increasingly competitive, characterized by frequent technological advancements and strategic collaborations. Companies that will succeed are those that maintain agility in their operations, capitalize on emerging technologies, and navigate regulatory landscapes effectively to bring new, effective treatments to market in a timely manner.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Drugs Market

The Cancer Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing number and awareness of cancer diseases
  • Governments and health organizations' supportive initiatives for cancer treatment
• Market Restraints
  • High R&D cost and product recall issues associated with cancer drug
• Market Opportunities
  • Advancements in genomic and molecular research leading to personalized cancer treatments
  • Increasing investment in generic medicine development
• Market Challenges
  • Stringent regulatory requirements associated with cancer drugs

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Drugs Market

A detailed market share analysis in the Cancer Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Drugs Market

A strategic analysis of the Cancer Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Biogen MA Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cipla Limited, Eli Lilly and Company, F. Hofmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Incyte Corporation, Ipsen Pharma, Johnson & Johnson Services, Inc., Mallinckrodt PLC, Merck KGaA, Novartis AG, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sanofi Group, Sumitomo Pharma Co., Ltd., Sun Pharmaceuticals Limited, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Route of Administration, market is studied across Intravenous, Oral, and Topical.
• Based on Type of Therapy, market is studied across Chemotherapy, Combination Therapy, Hormonal Therapy, Immunotherapy, Radiation Therapy, and Targeted Therapy.
• Based on Type, market is studied across Bladder Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Esophagus Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Prostate Cancer, and Stomach Cancer.
• Based on End-User, market is studied across Clinics, Homecare, and Hospitals.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing number and awareness of cancer diseases
    • 5.1.1.2. Governments and health organizations' supportive initiatives for cancer treatment
  • 5.1.2. Restraints
    • 5.1.2.1. High R&D cost and product recall issues associated with cancer drug
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in genomic and molecular research leading to personalized cancer treatments
    • 5.1.3.2. Increasing investment in generic medicine development
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulatory requirements associated with cancer drugs
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type of therapy : Increasing preference for immunotherapy due to its long-term remission and reduced side effects
  • 5.2.2. End-user : Rising preference for personalized medicine plans in homecare
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cancer Drugs Market, by Route of Administration

• 6.1. Introduction
• 6.2. Intravenous
• 6.3. Oral
• 6.4. Topical

7. Cancer Drugs Market, by Type of Therapy

• 7.1. Introduction
• 7.2. Chemotherapy
• 7.3. Combination Therapy
• 7.4. Hormonal Therapy
• 7.5. Immunotherapy
• 7.6. Radiation Therapy
• 7.7. Targeted Therapy

8. Cancer Drugs Market, by Type

• 8.1. Introduction
• 8.2. Bladder Cancer
• 8.3. Breast Cancer
• 8.4. Cervical Cancer
• 8.5. Colorectal Cancer
• 8.6. Esophagus Cancer
• 8.7. Kidney Cancer
• 8.8. Liver Cancer
• 8.9. Lung Cancer
• 8.10. Prostate Cancer
• 8.11. Stomach Cancer

9. Cancer Drugs Market, by End-User

• 9.1. Introduction
• 9.2. Clinics
• 9.3. Homecare
• 9.4. Hospitals

10. Americas Cancer Drugs Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Cancer Drugs Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Cancer Drugs Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Lantern Pharmaceuticals and OHSU Join Forces to Develop Advanced AI-Driven Cancer Treatments
  • 13.3.2. Ono Pharmaceutical Acquires Deciphera Pharmaceuticals in USD 2.4 Billion Deal to Bolster Oncology Portfolio
  • 13.3.3. Zydus Lifesciences Expands Cancer Treatment Options in India with Launch of New Drug Ibyra
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Amgen Inc.
• 3. Astellas Pharma Inc.
• 4. AstraZeneca PLC
• 5. Bayer AG
• 6. Biogen MA Inc.
• 7. Boehringer Ingelheim GmbH
• 8. Bristol-Myers Squibb Company
• 9. Cipla Limited
• 10. Eli Lilly and Company
• 11. F. Hofmann-La Roche Ltd.
• 12. Gilead Sciences, Inc.
• 13. GlaxoSmithKline PLC
• 14. Incyte Corporation
• 15. Ipsen Pharma
• 16. Johnson & Johnson Services, Inc.
• 17. Mallinckrodt PLC
• 18. Merck KGaA
• 19. Novartis AG
• 20. Pfizer, Inc.
• 21. Regeneron Pharmaceuticals, Inc.
• 22. Sanofi Group
• 23. Sumitomo Pharma Co., Ltd.
• 24. Sun Pharmaceuticals Limited
• 25. Takeda Pharmaceutical Company Limited
• 26. Teva Pharmaceutical Industries Ltd.